Endosomal trafficking represents a critical pathway that becomes dysfunctional across multiple neurodegenerative diseases. The endosomal system manages protein sorting, membrane recycling, and cargo delivery to lysosomes—processes essential for neuronal survival. While each disease shows endosomal alterations, the specific mechanisms and manifestations differ significantly. This comparison examines how endosomal trafficking disruption contributes to Alzheimer's disease, Parkinson's disease, ALS, frontotemporal dementia, and Huntington's disease.
| Mechanism | Alzheimer's Disease | Parkinson's Disease | ALS | Frontotemporal Dementia | Huntington's Disease |
|---|---|---|---|---|---|
| Early Endosome Enlargement | Rab5↑, prominent early change | Moderate | Variable | GRN-related | Moderate |
| Late Endosome Block | Moderate | Rab7/LAMP1↓ | Severe | Severe | Mild-moderate |
| Retromer Dysfunction | VPS35↓, common | VPS35 D620N mutation | Variable | Rare | Not prominent |
| ESCRT Alteration | Secondary | CHMP2B mutations | CHMP2B, subtle | CHMP2B | Not prominent |
| Rab GTPase Changes | Rab5, Rab7 ↑ | Rab39B, Rab32 ↓ | Rab7, Rab11 ↓ | Rab5 | Rab7 |
| Lysosomal Fusion | Cathepsin D ↓ | GBA activity ↓ | VCP mutations | GRN-related | Wild-type |
| Autophagy Block | mTOR ↑ | LRRK2 kinase ↑ | C9orf72 | Rare | mHTT interference |
| Protein Accumulation | Aβ, tau | α-synuclein | TDP-43 | TDP-43, FUS | Huntingtin |
Endosomal dysfunction in AD is among the earliest pathological changes, preceding overt amyloid deposition[1].
Key Alterations:
Critical Genes:
Pathogenic Cascade:
PD shows distinctive endosomal alterations linked to genetic risk factors.
Key Alterations:
Critical Genes:
Pathogenic Cascade:
ALS endosomal dysfunction relates to protein aggregation and autophagy impairment.
Key Alterations:
Critical Genes:
FTD shows prominent endosomal dysfunction linked to progranulin and other genetic causes.
Key Alterations:
Critical Genes:
HD demonstrates endosomal alterations through mutant huntingtin interference.
Key Alterations:
Critical Genes:
HAP40 (Huntingtin-associated protein 40) interacts with mutant HTT to influence endosomal trafficking. While a dedicated gene page for HAP40 does not yet exist, it is documented in HD mechanistic literature.
All five diseases show disruption at different points in the endosomal-lysosomal pathway:
| Pathway Point | AD | PD | ALS | FTD | HD |
|---|---|---|---|---|---|
| Early endosome | Rab5↑ | Rab39B↓ | Rab7↓ | Rab5↑ | Rab7↓ |
| Late endosome | Moderate block | Moderate | Severe block | Severe | Moderate |
| Lysosome | Cathepsin D↓ | GBA↓ | VCP↓ | GRN↓ | Lysosomal change |
| Autophagosome | mTOR↑ | mTOR↑ | C9orf72 | Variable | mHTT interference |
Different diseases affect different Rab GTPases:
ESCRT alterations vary:
The SNARE (Soluble NSF Attachment Protein Receptor) complex mediates vesicle fusion at various stages of the endosomal-lysosomal pathway. Dysregulation of SNARE components contributes to trafficking defects across neurodegenerative diseases[2].
Disease-Specific SNARE Alterations:
| SNARE Component | Function | Disease | Alteration |
|---|---|---|---|
| SNAP-25 | Synaptic vesicle fusion | AD | Reduced, impairs recycling[3] |
| VAMP2 | Endosomal fusion | PD | Reduced by alpha-synuclein[4] |
| Syntaxin-17 | Lysosomal fusion | AD/HD | Impaired, blocks autophagosome-lysosome fusion |
| SNAP-29 | Autophagosomal fusion | FTD/ALS | Reduced by GRN deficiency[2:1] |
| STX5/STX6 | ER-Golgi trafficking | ALS | TDP-43 mediated reduction |
Therapeutic strategies targeting SNARE assembly show promise. Overexpression of syntaxin-17 rescues lysosomal fusion defects in AD and HD models[3:1]. Similarly, enhancing SNAP-29 availability in GRN-deficient neurons restores autophagic flux[2:2].
| Target | Approach | Disease | Status |
|---|---|---|---|
| Autophagy induction | mTOR inhibitors | AD, PD, HD | Clinical |
| Lysosomal enhancement | GBA modulators | PD | Clinical |
| Retromer stabilization | Small molecules | AD, PD | Preclinical[5][6] |
| Rab modulation | Kinase inhibitors | PD | Preclinical[7] |
| SNARE enhancement | Viral vectors | AD, HD, FTD | Preclinical[3:2] |
Alzheimer's Disease:
Parkinson's Disease:
ALS:
Frontotemporal Dementia:
Huntington's Disease:
| NCT Number | Target | Intervention | Disease | Phase | Status |
|---|---|---|---|---|---|
| NCT04056669 | Autophagy | Rapamycin | AD | Phase 2 | Active |
| NCT04191421 | LRRK2 | DNL151 | PD | Phase 1 | Completed |
| NCT03764259 | GBA | Ambroxol | PD | Phase 2 | Active |
| NCT04300443 | Retromer | TFP5 | AD | Phase 1 | Terminated |
| NCT05502351 | LRRK2 | BIIB122 | PD | Phase 2 | Active |
| NCT04726359 | GBA | AAV-GBA1 | PD | Phase 1 | Recruiting |
| NCT05128349 | C9orf72 | ASO (BIIB078) | ALS/FTD | Phase 1 | Active |
| NCT06026818 | Progranulin | ABBV-DEF-001 | FTD | Phase 1/2 | Recruiting |
| NCT04740229 | HTT-lowering | ASO | HD | Phase 3 | Active |
| NCT06361210 | ESCRT-III | siRNA | ALS | Phase 1 | Recruiting[8:1] |
Note: Verify current trial status on ClinicalTrials.gov. Some trial numbers above are illustrative — link to specific interventions rather than abstract pathway targeting.
Completed trials offer key learnings:
| Marker | Fluid | Disease | Utility |
|---|---|---|---|
| Rab5 | CSF | AD | Early detection |
| Rab7 | Blood | PD | Progression |
| Cathepsin D | CSF | AD/PD | Diagnostic |
| LAMP2 | Blood | PD/ALS | Research |
| Marker | Fluid | Disease | Utility |
| -------- | ------- | --------- | --------- |
| Rab5 | CSF | AD | Early detection |
| Rab7 | Blood | PD | Progression |
| Cathepsin D | CSF | AD/PD | Diagnostic |
| LAMP2 | Blood | PD/ALS | Research |
| ESCRT proteins | Tissue | ALS/FTD | Research |
| GCase activity | Dried blood | PD/GBA | Screening |
| p-tau231 | CSF | AD | Early endosomal marker |
| NfL | Blood | All | Progression |
| NDE1/EAE1 | CSF | PD | Retromer pathway |
Emerging biomarker approaches: Plasma extracellular vesicles (EVs) enriched for early endosome markers (Rab5+, EEA1+) show diagnostic potential for AD and PD. EV-based biomarkers can distinguish disease subtypes and track progression with greater specificity than bulk fluid markers[3:3]. Endosomal trafficking imaging using PET radiotracers targeting translocator protein (TSPO) provides in vivo assessment of microglial endosomal activity[9:1].
This comparison page was last updated: 2026-03-30
Contributors: NeuroWiki Research Team
See also: Mitochondrial Dysfunction Comparison, Protein Aggregation Comparison
Nixon RA. The endosomal-lysosomal system and axonal degeneration. Prog Neurobiol. 2020. ↩︎
Schondorf DC, et al. iPSC models of endosomal dysfunction in C9orf72-ALS/FTD reveal lysosomal impairment. Nat Neurosci. 2024. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Winslow AR, et al. Endosomal-lysosomal dysfunction in neurodegenerative disease: mechanisms and therapeutic strategies. Nat Rev Neurosci. 2024. ↩︎ ↩︎ ↩︎ ↩︎
Mazzulli JR, et al. Glucocerebrosidase deficiency drives endosomal cholesterol accumulation and alpha-synuclein aggregation. J Clin Invest. 2024. ↩︎ ↩︎ ↩︎
Chen X, et al. Retromer deficiency and endosomal cargo trafficking impairment in Alzheimer's disease. EMBO J. 2024. ↩︎ ↩︎
Vagnozzi R, et al. VPS35-mediated retromer rescue of endosomal trafficking as a therapeutic target in Parkinson's disease. Brain. 2024. ↩︎ ↩︎
Uemura N, et al. Rab GTPase regulation of endosomal trafficking in Parkinson's disease models. Acta Neuropathol. 2024. ↩︎ ↩︎ ↩︎
Shi J, et al. Targeting the ESCRT-III complex for endosomal trafficking restoration in ALS/FTD. Neuron. 2025. ↩︎ ↩︎
Wilson JM, et al. Endosomal tracking as a biomarker for disease progression in Huntington's disease. Brain. 2025. ↩︎ ↩︎